Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Product Development

Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report

Plus: Readouts from Sanofi-Teva, Bicycle and more

By Lauren Martz, Executive Director, Biopharma Intelligence, and Gunjan Ohri, Data Content Analyst
December 18, 2024 12:52 AM UTC

A week of positive clinical outcomes that drove up share prices was bogged down by a trio of product discontinuations in once highly promising therapeutic classes.

The past seven days saw Merck & Co. Inc. (NYSE:MRK) discontinue development of two next-generation checkpoint inhibitors that were once poised as Keytruda pembrolizumab follow-ons...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Bicycle Therapeutics plc

Corcept Therapeutics Inc.

Edgewise Therapeutics Inc.

Foghorn Therapeutics Inc.

Keros Therapeutics Inc.

Merck & Co. Inc.

Pfizer Inc.